Holen Sie sich die Stockscreener-App
173.34
0.78%
1.34
Handel nachbörslich:
173.34
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$172.00
Offen:
$172.22
24-Stunden-Volumen:
1.61M
Relative Volume:
1.22
Marktkapitalisierung:
$19.35B
Einnahmen:
$9.54B
Nettoeinkommen (Verlust:
$841.00M
KGV:
23.30
EPS:
7.44
Netto-Cashflow:
$1.02B
1W Leistung:
+1.23%
1M Leistung:
-2.89%
6M Leistung:
+6.57%
1J Leistung:
+24.41%
1-Tages-Spanne:
$171.36
$173.42
1-Wochen-Bereich:
$170.59
$173.95
52-Wochen-Spanne:
$135.47
$179.99
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Vergleichen Sie DGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
173.34 | 19.12B | 9.54B | 841.00M | 1.02B | 7.44 |
|
TMO
Thermo Fisher Scientific Inc
|
402.82 | 148.60B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.90 | 132.07B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
513.36 | 40.34B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
111.92 | 30.82B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
140.33 | 23.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years - Benzinga
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Quest Diagnostics (DGX) Participates in Upcoming Oppenheimer Meeting | DGX Stock News - GuruFocus
HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick? - The Globe and Mail
Is Wall Street Bullish or Bearish on Quest Diagnostics Stock? - inkl
Is Wall Street Bullish Or Bearish On Quest Diagnostics Stock? - Barchart.com
Quest Diagnostics' $4M Rest Break Settlement Gets Initial OK - Law360
Quest Diagnostics (DGX) Announces Results of 2025 Annual Meeting of Stockholders - GuruFocus
Quest Diagnostics Inc (DGX) Shares Gap Down to $171.44 on May 21 - GuruFocus
What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year? - Yahoo Finance
Quest Diagnostics stock hits all-time high of $179.37 By Investing.com - Investing.com Nigeria
Director Diaz Luis was granted 1,203 shares, increasing direct ownership by 42% to 4,054 units (SEC Form 4) - Quantisnow
Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference - PR Newswire
Lung Cancer Diagnostics Market Outlook: Opportunities in Early - openPR.com
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock - Yahoo Finance
Quest Diagnostics CEO Reveals Future Growth Strategy: Key Insights Coming at William Blair Conference - Stock Titan
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock - Yahoo Finance
Insider Sell: Mark Delaney Sells Shares of Quest Diagnostics Inc (DGX) - GuruFocus
Quest Diagnostics Keeps Dividend at $0.80 per Share, Payable July 21 to Shareholders as of July 7 - marketscreener.com
Quest Diagnostics (DGX) Declares Consistent Dividend - GuruFocus
Quest Diagnostics Declares Quarterly Cash Dividend - PR Newswire
Quest Diagnostics : Forbes Names Quest Diagnostics One of America's Best Large Employers - marketscreener.com
Quest Diagnostics Declares Quarterly Cash Dividend, Payable on July 21, 2025 - marketscreener.com
Is Quest Diagnostics Incorporated's (NYSE:DGX) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - Yahoo
Should You Continue to Retain DGX Stock in Your Portfolio? - TradingView
Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds - Quantisnow
Global Immunodiagnostics Market to Cross the USD 32 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
Quest Diagnostics (DGX) Sees Raised Target Price by JP Morgan | - GuruFocus
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Quest Diagnostics (DGX) Receives Price Target Increase from JPMo - GuruFocus
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus - MSN
Quest Diagnostics Stock: A Leader But Waiting For Better Price (NYSE:DGX) - Seeking Alpha
Quest Settles Fired Black Phlebotomist's Retaliation Suit - Law360
Bullish on Quest Diagnosis Inc. - The Globe and Mail
This Company Extended Its Post-Earnings Rally to Record Highs - The Globe and Mail
Labcorp beats quarterly profit estimate on diagnostic test demand - Reuters
Fitch elevates Quest Diagnostics’ rating to ’BBB+’ with stable outlook By Investing.com - Investing.com Canada
Fitch elevates Quest Diagnostics’ rating to ’BBB+’ with stable outlook - Investing.com
Piper Sandler Adjusts Price Target on Quest Diagnostics to $200 From $180, Maintains Neutral Rating - marketscreener.com
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight - GuruFocus
Truist Financial Keeps Their Hold Rating on Quest Diagnostics (DGX) - The Globe and Mail
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings - Benzinga
Morgan Stanley Adjusts Quest Diagnostics Price Target to $182 From $172, Maintains Overweight Rating - marketscreener.com
Baird Adjusts Quest Diagnostics Price Target to $194 From $191, Maintains Outperform Rating - marketscreener.com
Jefferies Adjusts Quest Diagnostics Price Target to $195 From $190, Maintains Buy Rating - marketscreener.com
Quest Diagnostics (DGX) Sees Price Target Increase Following Str - GuruFocus
Mizuho Securities Adjusts Quest Diagnostics Price Target to $190 From $189 - marketscreener.com
Quest Diagnostics (DGX) Sees Price Target Increase Following Strong Q1 Results | DGX Stock News - GuruFocus
A Glimpse Into The Expert Outlook On Quest Diagnostics Through 12 Analysts - Benzinga
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.71%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):